Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
The DOI matches its Crossref record.
Abstract
3005^ Background: MK-3475 demonstrated antitumor activity and acceptable safety in a phase I MEL cohort. We provide updated efficacy data and correlation with tumor PD-L1 expression. Methods: 135 pts received MK-3475 10 mg/kg Q2W (n = 57), 10 mg/kg Q3W (n = 56), or 2 mg/kg Q3W (n = 22). Response was assessed every 12 wk by RECIST 1.1 by independent central review and by immune-related response criteria (irRC) by investigator. Biopsy was required in the 60 d before MK-3475. Tumor PD-L1 expression was assessed by IHC. A preliminary cutoff of 1% of stained tumor cells defined PD-L1 positivity. Results: As of 10/18/2013, all pts had ≥13 mo follow-up. Median time on treatment was 23 wk (range, 1 dose to 97 wk). In pts with measurable disease, ORR was 41% by RECIST (Table). Objective responses were observed as late as 64 wk, with some conversions to CR seen as late as 72 wk. Median response duration was not reached; responses were ongoing for 87% of responders. Median PFS was 31 wk. Median OS was not reached, and OS rate at 1 y was 81%. Tumor PD-L1 expression was evaluable in 71 pts with measurable disease and ≥1 tumor evaluation (77% PD-L1+). Of these pts, PD-L1 expression was associated with improved ORR by RECIST (51% vs 6%, P = .0012 [Fisher’s exact]) and PFS (median 12 vs 3 mo, HR 0.31, 95% CI 0.16-0.61, P = .0004 [log-rank]). 1-y OS rate was 84% in PD-L1+ and 69% in PD-L1– pts (P = .2146 [log-rank]). There were no treatment-related deaths; 14% of pts experienced drug-related grade 3/4 AEs. Conclusions: MK-3475 induces durable responses and favorable 1-y OS with acceptable safety in MEL. Although tumor PD-L1 positivity was associated with improved ORR and PFS, antitumor activity was also observed in pts with low baseline PD-L1 expression. These preliminary data require confirmation. Clinical trial information: NCT01295827. RECIST 1.1 irRC 2 Q3W 10 Q3W 10 Q2W Total 2 Q3W 10 Q3W 10 Q2W Total ORR, % (95% CI) 45 (23-69) 31 (18-47) 49 (35-63) 41 (32-51) 32 (14-55) 32 (20-46) 58 (44-71) 43 (35-52) Median response duration, wk (range) NR (9+ – 60+) NR (11 – 72+) NR (8+ – 76+) NR (8+ – 76+) NR (9 – 60+) NR (11 – 65+) NR (12 – 93+) NR (9 – 93+) Median PFS, wk (95% CI) 72 (12-NR) 24 (12-36) 50 (24-NR) 31 (19-50) 72 (12-NR) 30 (15-NR) 84 (24-NR) 54 (24-NR) 24-wk PFS, % 56 44 60 53 51 54 64 58
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
“Pembrolizumab (anti-PD-1) has also been studied in advanced melanoma utilizing an IHC cutoff of 1% (70).”
BackgroundLu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, J. M., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 607
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Self-citationThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Sunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
Metadata
- Authors
- Kefford, R., Ribas, A., Hamid, O., Robert, C., Daud, A., Wolchok, J. D., Joshua, A. M., Hodi, F. S., Gangadhar, T. C., Hersey, P., Weber, J. S., Dronca, R. S., Patnaik, A., Zarour, H. M., Dolled-Filhart, M., Lunceford, J., Emancipator, K., Ebbinghaus, S., Kang, S. P., & Hwu, W.-J.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-20
- Volume
- 32
- Issue
- 15_suppl
- Pages
- 3005-3005
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2908271323
- Cited by
- 89
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.3005
- The paper
- Kefford, R., Ribas, A., Hamid, O., Robert, C., Daud, A., Wolchok, J. D., Joshua, A. M., Hodi, F. S., Gangadhar, T. C., Hersey, P., Weber, J. S., Dronca, R. S., Patnaik, A., Zarour, H. M., Dolled-Filhart, M., Lunceford, J., Emancipator, K., Ebbinghaus, S., Kang, S. P., & Hwu, W.-J. (2014). Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.3005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.